Trending...
- DriveYo Signs Cybersecurity Prodigy and Open-Source Pioneer Utkarsh Lubal
- Rabbi Michael Rothschild (#ViralRabbi) to Discuss Futurism on the Popular "The Mike Holt Show"
- Century Fasteners Corp. Exhibiting at 2026 MRO Americas Show – April 21-23, 2026 – Booth #2257
ANNAPOLIS, Md., Jan. 10, 2025 ~ In an exciting announcement, Alphyn, a clinical-stage dermatology company, revealed that their CEO Neal Koller will be presenting at several investor conferences during the upcoming J.P. Morgan Healthcare Week in San Francisco.
The first conference, Biotech Showcase, will take place on January 13th at 10:45 a.m. at the Hilton San Francisco Union Square. Mr. Koller will then move on to the Redefining Every Stage of Investment (RESI) JPM conference on January 14th at 11 a.m. at the San Francisco Marriott Marquis. He has been selected as a finalist in the RESI Innovators Pitch Challenge.
Later that same day, Mr. Koller will also be speaking at NEXUS 2025 from 3 p.m. to 9 p.m. at the Hanger in South San Francisco. During these presentations, he will provide an overview of Alphyn's corporate developments and discuss their lead product candidate, Zabalafin Hydrogel.
More on The Californer
Zabalafin Hydrogel is currently in development to treat atopic dermatitis (AD), a chronic skin condition that affects millions of people worldwide. It is set to begin Phase 2b clinical trials this year and has shown promising results in treating all aspects of AD - including bacterial causes and exacerbation of the disease, as well as managing symptoms such as itchiness, inflammation, and infection.
Alphyn's second candidate is aimed at treating epidermolysis bullosa, a group of rare and potentially fatal skin diseases. With these innovative Multi-Target Therapeutics®, Alphyn hopes to make significant advancements in the field of dermatology and improve the quality of life for those suffering from these conditions.
Investors and industry professionals alike are eagerly anticipating Mr. Koller's presentations and updates on Alphyn's groundbreaking clinical programs during J.P Morgan Healthcare Week next week in San Francisco.
The first conference, Biotech Showcase, will take place on January 13th at 10:45 a.m. at the Hilton San Francisco Union Square. Mr. Koller will then move on to the Redefining Every Stage of Investment (RESI) JPM conference on January 14th at 11 a.m. at the San Francisco Marriott Marquis. He has been selected as a finalist in the RESI Innovators Pitch Challenge.
Later that same day, Mr. Koller will also be speaking at NEXUS 2025 from 3 p.m. to 9 p.m. at the Hanger in South San Francisco. During these presentations, he will provide an overview of Alphyn's corporate developments and discuss their lead product candidate, Zabalafin Hydrogel.
More on The Californer
- Expert Law Attorneys' Top Law Firms to Know: March 2026
- Quinceañera Expo 2026: A Parisian Dream Comes to Los Angeles
- Thorn & Bloom Magazine Releases Fifth Issue: Rooted & Ruptured
- California celebrates Genentech's 50th anniversary
- Sonnenblick-Eichner Company Arranges $26 Million Loan to Refinance San Francisco area hotel
Zabalafin Hydrogel is currently in development to treat atopic dermatitis (AD), a chronic skin condition that affects millions of people worldwide. It is set to begin Phase 2b clinical trials this year and has shown promising results in treating all aspects of AD - including bacterial causes and exacerbation of the disease, as well as managing symptoms such as itchiness, inflammation, and infection.
Alphyn's second candidate is aimed at treating epidermolysis bullosa, a group of rare and potentially fatal skin diseases. With these innovative Multi-Target Therapeutics®, Alphyn hopes to make significant advancements in the field of dermatology and improve the quality of life for those suffering from these conditions.
Investors and industry professionals alike are eagerly anticipating Mr. Koller's presentations and updates on Alphyn's groundbreaking clinical programs during J.P Morgan Healthcare Week next week in San Francisco.
Filed Under: Business
0 Comments
Latest on The Californer
- City of Long Beach Celebrates Earth Month with Events Throughout April
- Fans Are Becoming the New Discovery Engine for Music Through The Ultimate F.A.N. Collective
- Riggo Production Studio Launches Monthly Content Package for Growing Brands
- Accelerating into Active Oil Production with over 100 Barrels per day now being produced as Dual-revenue engine begins Generating Cash Flow: $IBG
- Finland emerges as clear Eurovision 2026 favourite – analysis of 12 bookmakers by Vedonlyöntisivut
- Mac Mountain Selects netElastic vRouter for LightCraft Broadband-as-a-Service Platform
- A Kickstarter Campaign for "A Cable To The Moon"
- California Watermelon Festival "A Sweet Slice of California"
- Oceanside Bombers Team Up with Bragabilia Energy for Limited‑Edition "Quiet Flex" Cans
- Frequent Coffee Sets New Record with 94-Point Decaf Score
- CMSWire Announces 2026 Customer Experience Leader of the Year and IMPACT Award Winners
- Reworked Announces 2026 Leaders of the Year and IMPACT Award Honorees
- California BPPE Approves Institutional Name Change from PhlebotomyU to HealthCareerU
- 88% Revenue Growth; Charging Into the Future with Explosive Growth, Strategic EV Expansion and Infrastructure Dominance Signal a Breakout Opportunity
- Forge Resources Unlocks Major Gold-Copper System in Yukon as Drilling Success and Strategic Assets Fuel High-Impact Growth Story for: $FRGGF
- PasskeyBridge Launches Patent-Pending Identity Threat Response Platform With Zero PII Storage
- Economist N. Robert Branch to Headline Summit for Economic Liberalism; Target 10,000 LA Attendees
- EXCLUSIVE: Slam City's Speed Shift Origins Gains Financing and Distribution Momentum; Mike Ryan Joins as Stunt Director
- Filmmaker Domenic Migliore Announces Anthology Series "Evermore: Tales from the Mind of Poe"
- Actor Cody Derr Announces New Representation